Evidence map›Paper›PMID 27317482›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2016

Prospective evaluation of [

Sarah M Schwarzenböck, Matthias Eiber, Günther Kundt, Margitta Retz, Monique Sakretz, Jens Kurth, Uwe Treiber, Roman Nawroth, Ernst J Rummeny, Jürgen E Gschwend and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Distinct prognostic value of [Communications medicine · 2026
    Article
  3. Review
  4. Review
  5. Exploratory study ofAmerican journal of nuclear medicine and molecular imaging · 2021
    Article
  6. Review
  7. European journal of nuclear medicine and molecular imaging · 2019
    Article
  8. Prognostic Value ofContrast media & molecular imaging · 2019
    Article
  9. Article
  10. Review
  11. European journal of nuclear medicine and molecular imaging · 2018
    Article
  12. Preliminary results on response assessment usingEuropean journal of nuclear medicine and molecular imaging · 2018
    Article
  13. Review
  14. Review
  15. Review
  16. Therapy assessment in prostate cancer using choline and PSMA PET/CT.European journal of nuclear medicine and molecular imaging · 2017
    Review
  17. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2016
    Article
  18. Article
  19. Review
  20. One-year experience withRadiologia brasileira
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sarah M SchwarzenböckDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. sarah.schwarzenboeck@med.uni-rostock.de.
Matthias EiberDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Günther KundtDepartment of Biostatistics and Informatics, Rostock University Medical Centre, Ernst-Heydemann-Str. 8, 18057, Rostock, Germany.
Margitta RetzDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Monique SakretzDepartment of Nuclear Medicine, Rostock University Medical Centre, Gertrudenplatz 1, 18057, Rostock, Germany.
Jens KurthDepartment of Nuclear Medicine, Rostock University Medical Centre, Gertrudenplatz 1, 18057, Rostock, Germany.
Uwe TreiberDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Roman NawrothDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Ernst J RummenyInstitute of Radiology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Jürgen E GschwendDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Markus SchwaigerDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Mark ThalgottDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Bernd J KrauseDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Klinikum rechts der Isar · DEUniversity of Rostock · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to prospectively evaluate the value of [

methodsThirty-two patients were referred for [

resultsIn the patient-based ERA and LRA there were no statistically significant differences in change of choline uptake, HU, and volume between PD and nPD applying RECIST or clinical response criteria. In the lesion-based ERA, decrease in choline uptake of bone metastases was even higher in PD (applying RECIST criteria), whereas in LRA the decrease was higher in nPD (applying clinical criteria). There were only significant correlations between change in choline uptake and PSA in ERA in PD, in LRA no significant correlations were discovered. Initial SUV

conclusionThere is no significant correlation between change in choline uptake in [

Indexed as

CholineAgedAged, 80 and overAntineoplastic AgentsCarbon RadioisotopesDocetaxelDrug Administration ScheduleDrug MonitoringHumansImage EnhancementMaleMiddle AgedOutcome Assessment, Health CarePositron Emission Tomography Computed TomographyProspective StudiesProstatic Neoplasms, Castration-ResistantAntineoplastic AgentsCarbon RadioisotopesCholineDocetaxelRadiopharmaceuticalsTaxoidsAdvanced prostate cancerCholineDocetaxel therapyPET/CTTherapy response assessment

Identifiers

PMID27317482
OpenAlexW2440646255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.